RxDoctor Payments Data

Mark Walker

Optometrist · Elkhart, INNPI 1972731461

Payments from drug & device makers

$3,157in general payments, 2019–2025

Across 75 payments — averaging $42.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$741
  • Glaukos Corporation$335
  • Amgen$271
  • Mallinckrodt Hospital Products Inc.$232
  • Biotissue Holdings Inc.$218
  • Shire North American Group Inc$161
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,157100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,157 in reported general payments places this provider in the 85th percentile of 1,318 optometrist providers in Indiana.

See all optometrist providers in Indiana

Medicare billing

Part B allowed, 2024
$160,676
Medicare patients
750
Services billed
2,143

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine52$73,532
LumiganBimatoprost87$58,333
XiidraLifitegrast15$30,111
Cyclosporine29$9,575
Loteprednol Etabonate46$7,081
CombiganBrimonidine Tartrate/Timolol19$6,323
Travoprost12$2,752
Prednisolone Acetate71$2,606
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat166$2,108
Fluorometholone24$1,685
Latanoprost313$1,672
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol18$1,361
Tobramycin-DexamethasoneTobramycin/Dexamethasone28$1,304
ValacyclovirValacyclovir Hcl20$1,060
Timolol Maleate99$1,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$65$138,188158 claims
Bausch & Lomb Americas Inc.Xiidra$53$30,11115 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$79$7,08146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,318 optometrist providers in Indiana.

Other optometrist in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →